Education
About Us
Working with TipRanks
Follow Us
Medrx Co., Ltd. (JP:4586)
:4586
Top Page
Medrx Co., Ltd.
(4586)
41Neutral
Medrx Co., Ltd. (4586) vs. S&P 500 (SPY)
Market Cap
¥3.04B
Dividend YieldN/A
Average Volume (3M)944.16K
Price to Earnings (P/E)―
Beta (1Y)1.45
Revenue Growth773.28%
EPS Growth35.71%
CountryJP
Employees22
SectorHealthcare
Sector Strength65
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-17.52
Shares Outstanding47,495,100
10 Day Avg. Volume1,425,400
30 Day Avg. Volume944,160
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Medrx Co., Ltd. Business Overview & Revenue Model
Company DescriptionMedrx Co., Ltd. (4586) is a Japan-based company primarily engaged in the research, development, manufacturing, and distribution of pharmaceutical products. The company specializes in transdermal drug delivery systems, which allow medications to be absorbed through the skin. Medrx Co., Ltd. focuses on providing innovative healthcare solutions across various therapeutic areas, enhancing patient compliance, and improving treatment outcomes.
How the Company Makes MoneyMedrx Co., Ltd. generates revenue through the development and commercialization of its proprietary transdermal drug delivery systems. The company's revenue streams include the sale of pharmaceutical products, licensing agreements with other pharmaceutical companies, and collaborative partnerships for research and development. Additionally, Medrx Co., Ltd. may earn income through milestone payments and royalties from the commercialization of products developed in collaboration with other entities. The company's focus on innovation and strategic partnerships plays a significant role in its earnings potential.
Medrx Co., Ltd. Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 257.00M | 29.00M | 59.48M | 8.35M | 115.09M | Gross Profit |
| 257.00M | 26.00M | 56.86M | 6.09M | 111.18M | EBIT |
| -793.00M | -933.00M | -1.10B | -1.06B | -1.13B | EBITDA |
| -755.00M | -884.52M | -1.05B | -996.66M | -1.05B | Net Income Common Stockholders |
| -806.00M | -932.00M | -1.11B | -1.06B | -1.11B |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 1.98B | 1.72B | 994.02M | 1.70B | 1.81B | Total Assets |
| 2.27B | 2.05B | 1.40B | 2.11B | 2.30B | Total Debt |
| 0.00 | 0.00 | 0.00 | 0.00 | 50.00M | Net Debt |
| -1.98B | -1.72B | -994.02M | -1.70B | -1.76B | Total Liabilities |
| 107.00M | 129.00M | 185.56M | 153.10M | 149.88M | Stockholders Equity |
| 2.17B | 1.92B | 1.21B | 1.96B | 2.15B |
| Cash Flow | Free Cash Flow | |||
| -803.00M | -913.76M | -1.08B | -926.23M | -1.02B | Operating Cash Flow |
| -803.00M | -913.00M | -1.07B | -923.69M | -985.35M | Investing Cash Flow |
| 0.00 | 0.00 | -1.96M | -2.54M | -5.10M | Financing Cash Flow |
| 1.07B | 1.64B | 356.31M | 815.91M | 1.39B |
Medrx Co., Ltd. Technical Analysis
Negative
64.00
Price Trends
77.00
Negative
80.23
Negative
93.42
Negative
Market Momentum
-4.34
Negative
41.99
Neutral
36.34
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4586, the sentiment is Negative. The current price of 64 is below the 20-day moving average (MA) of 67.45, below the 50-day MA of 77.00, and below the 200-day MA of 93.42, indicating a bearish trend. The MACD of -4.34 indicates Negative momentum. The RSI at 41.99 is Neutral, neither overbought nor oversold. The STOCH value of 36.34 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4586.
Medrx Co., Ltd. Peers Comparison
Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $5.31B | 3.33 | -39.82% | 2.92% | 17.95% | 1.84% | |
47 Neutral | ¥8.74B | ― | ― | 14.41% | 27.42% | ||
44 Neutral | ¥23.35B | ― | -186.22% | ― | 320.72% | -164.82% | |
43 Neutral | ¥76.69B | ― | -7.02% | ― | 125.87% | 38.07% | |
41 Neutral | ¥3.04B | ― | ― | 773.28% | 35.71% | ||
39 Underperform | ¥164.34B | ― | -123.63% | ― | ― | -3.32% | |
36 Underperform | ¥9.60B | ― | -19.08% | ― | -30.46% | 39.41% |
* Healthcare Sector Average
Performance Comparison
JP:4586
Medrx Co., Ltd.
64.00
-48.00
-42.86%
JP:4583
Chiome Bioscience Inc.
130.00
7.00
5.69%
JP:4571
NanoCarrier Co., Ltd.
136.00
-41.00
-23.16%
JP:4565
Sosei Group
885.00
-610.00
-40.80%
JP:4592
SanBio Co
1,898.00
1,485.00
359.56%
JP:4563
AnGes
72.00
23.00
46.94%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.